Compound ID | 808
Class: Oxazolidinone
| Spectrum of activity: | Gram-positive & Gram-negative |
| Details of activity: | Protein synthesis inhibitor; Designed to target respiratory tract infections |
| Institute where first reported: | Bayer AG, Business Group Pharma Res., Germany |
| Year first mentioned: | 2000 |
| Highest developmental phase: | Preclinical |
| Development status: | Inactive |
| External links: | |
| Citation: |